Care Setting Analysis: Hospital vs Home Care
Where the patient is matters more than ever.
How care is shifting from hospital to home — and what it means for pharma launch strategy, drug administration, RPM and digital health.
"How should our launch and channel strategy reflect the hospital-to-home shift?"
Acute care is consolidating into hospitals while chronic and post-acute care moves home. Subcutaneous and oral formulations win share over IV; RPM, home infusion and home-care nursing networks become primary channels.
The single biggest structural shift in pharma channel strategy this decade is care moving out of the hospital. It rewrites where launches happen, how patients adhere, and which products win share.
Why the shift is durable
CMS hospital-at-home reimbursement, SC formulations, RPM scale and labor economics all push the same direction. This is not a pandemic blip — it is a 10-year structural realignment.
Implications for pharma launches
SC over IV. Specialty + home-infusion partnerships built into the launch plan. RPM data tied back to RWE. Country playbooks differentiated by reimbursement. Pharma teams who treat care setting as a launch variable, not a fixed input, win share.
What we’re seeing in the data.
Hospital-at-home is now reimbursed
CMS waivers and private-payer programs are creating durable reimbursement for hospital-level care delivered at home.
SC and oral formulations gain share
IV-to-SC switches in oncology and immunology accelerate home-administration economics.
Home infusion economics improve
Specialty pharmacy + home-infusion networks scale to support biologics and ATMPs.
Patient-monitoring data closes loops
RPM data feeds back into provider and pharma decision systems, improving real-world outcomes evidence.
How to think about it.
-
01
Map indication to care setting
Acute, chronic, post-acute — each has different geo-economics.
-
02
Score formulation flexibility
IV-only assets face structural disadvantage as care shifts home.
-
03
Plan administration network
Home infusion, specialty pharmacy and nursing partner footprints.
-
04
Build RPM/data feedback loop
Wearables, devices and apps for adherence + safety + RWE.
-
05
Localize country playbooks
Reimbursement for home delivery varies sharply by country.
What separates a good answer from a defensible one.
Home-care nursing supply is a real constraint in many markets.
Some payers still reimburse home care less than hospital — model the gap.
Older patient populations adopt RPM unevenly — segment carefully.
Decentralized administration raises brand-experience variance — invest in HUB services.
Where the signal comes from.
Common questions.
Which therapy areas are shifting fastest?
Onc supportive care, immunology, RA and chronic disease management. Acute oncology infusion is shifting more slowly.
What does this mean for biologics launches?
SC formulation strategy and a home-infusion network become first-order launch decisions, not afterthoughts.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist